Jones Financial Companies Lllp raised its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 71.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,590 shares of the biopharmaceutical company's stock after buying an additional 2,750 shares during the quarter. Jones Financial Companies Lllp's holdings in Intra-Cellular Therapies were worth $550,000 at the end of the most recent quarter.
Other hedge funds have also made changes to their positions in the company. US Bancorp DE raised its holdings in Intra-Cellular Therapies by 3.3% in the third quarter. US Bancorp DE now owns 7,951 shares of the biopharmaceutical company's stock valued at $582,000 after acquiring an additional 251 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in shares of Intra-Cellular Therapies by 3.3% during the third quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company's stock worth $43,735,000 after purchasing an additional 18,865 shares during the period. Assetmark Inc. lifted its holdings in shares of Intra-Cellular Therapies by 9.1% during the third quarter. Assetmark Inc. now owns 2,477 shares of the biopharmaceutical company's stock worth $181,000 after purchasing an additional 207 shares during the period. Atria Investments Inc lifted its holdings in shares of Intra-Cellular Therapies by 41.1% during the third quarter. Atria Investments Inc now owns 5,137 shares of the biopharmaceutical company's stock worth $376,000 after purchasing an additional 1,497 shares during the period. Finally, Covestor Ltd lifted its holdings in Intra-Cellular Therapies by 40.4% in the third quarter. Covestor Ltd now owns 1,811 shares of the biopharmaceutical company's stock valued at $133,000 after acquiring an additional 521 shares during the period. Institutional investors and hedge funds own 92.33% of the company's stock.
Wall Street Analyst Weigh In
A number of research firms have commented on ITCI. Needham & Company LLC reissued a "hold" rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Cantor Fitzgerald raised Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, January 14th. Canaccord Genuity Group downgraded Intra-Cellular Therapies from a "buy" rating to a "hold" rating and lifted their price target for the stock from $119.00 to $132.00 in a research note on Friday, January 31st. StockNews.com initiated coverage on Intra-Cellular Therapies in a research note on Wednesday. They set a "hold" rating for the company. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $132.00 price target (up previously from $107.00) on shares of Intra-Cellular Therapies in a research note on Tuesday, January 14th. Ten investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $106.08.
Check Out Our Latest Research Report on Intra-Cellular Therapies
Intra-Cellular Therapies Price Performance
Intra-Cellular Therapies stock traded down $0.10 during midday trading on Friday, hitting $131.26. 1,500,320 shares of the company were exchanged, compared to its average volume of 1,323,524. The company's fifty day moving average price is $123.00 and its 200-day moving average price is $94.99. The company has a market cap of $13.96 billion, a PE ratio of -150.87 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a fifty-two week low of $63.30 and a fifty-two week high of $131.38.
Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. On average, analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.
About Intra-Cellular Therapies
(
Free Report)
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Recommended Stories
Before you consider Intra-Cellular Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.
While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
